What is Bicara Therapeutics's federal?

Bicara Therapeutics (BCAX) reported federal of $0 in Q4 2025.

What does federal mean?

This represents the change in deferred federal income tax assets and liabilities during the period, resulting from temporary differences between financial reporting and tax reporting. It indicates future tax consequences of events already recognized in the financial statements. This metric is essential for evaluating the company's long-term tax planning and future cash flow implications.

Bicara Therapeutics BCAX Federal

Federal at other companies

PhotronicsPLAB

-$3.58M—

V2XVVX

$1.89M-3.5%

ADMA BiologicsADMA

$2.35M+113%

EAT

Brinker InternationalEAT

$3.8M+184%

Corebridge FinancialCRBG

$86.75M-44.4%

UFP TechnologiesUFPT

$1.13M+334%

Other financials

Income statement

See full

Operating income-$60.2M-44.2%

Net income-$56.2M-52.6%

EPS (diluted)-$0.93-36.8%

Balance sheet

See full

Cash & equivalents$323.5M-30.0%

Total debt$1.4M+144%

Total equity$514.0M+12.0%

Total assets$553.6M+15.8%

Cash flow

See full

Operating cash flow-$37.5M-33.5%

CapEx$60.0K—

Free cash flow-$37.6M-33.7%

Valuation

See full

Market cap$1.68B+81.4%

Returns & leverage

See full

Return on equity-32.3%—

Debt / equity0×0.0×

Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DeferredFederalIncomeTaxExpenseBenefit.

The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's federal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bicara Therapeutics's federal?: Bicara Therapeutics (BCAX) reported federal of $0 in Q4 2025.
What does federal mean?: This represents the change in deferred federal income tax assets and liabilities during the period, resulting from temporary differences between financial reporting and tax reporting. It indicates future tax consequences of events already recognized in the financial statements. This metric is essential for evaluating the company's long-term tax planning and future cash flow implications.